Skip to main content

Health condition · Clinically reviewed

Geographic atrophy, the advanced form of dry AMD - and what to do about it.

A slow, relentless loss of central vision over years. Lifestyle, AREDS2, low vision rehabilitation and the newer complement inhibitors all now have a place - if you know where to look.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK medical retina clinician before publication.

  • 02

    Sourced from guidance

    Checked against the Royal College of Ophthalmologists, NICE and peer-reviewed retina literature you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including AREDS2 supplementation, low vision rehabilitation and the newer complement inhibitors.

Key facts

Geographic atrophy at a glance.

The essentials in plain English - what it is, how it is confirmed and where care sits in the UK today. For the broader condition, see our guide to age-related macular degeneration.

  • What it is

    The advanced form of dry age-related macular degeneration (AMD) - well-demarcated areas of retinal pigment epithelium, photoreceptor and choriocapillaris loss.

  • Who it affects

    Overwhelmingly people over 65, more common with age, family history and cardiovascular risk.

  • How it presents

    Gradual central and paracentral vision loss, scotomas, reduced contrast and difficulty reading - often bilateral but asymmetric.

  • How it is confirmed

    Slit lamp and dilated fundoscopy, OCT and fundus autofluorescence (FAF), which is the gold standard for measuring atrophy.

  • Foundation care

    Smoking cessation, a Mediterranean-style diet, AREDS2 supplementation and specialist low vision rehabilitation.

  • New medical options

    Intravitreal complement inhibitors (pegcetacoplan and avacincaptad pegol) slow atrophy growth but do not restore vision.

Why this guide matters

A slow condition where small choices add up.

Geographic atrophy will not disappear, but the trajectory is not fixed. The three points below shape everything else on this page.

  • Imaging is the anchor

    Fundus autofluorescence and OCT define the diagnosis, stage the disease and measure whether treatment is slowing atrophy growth.

  • Lifestyle still matters most

    Smoking cessation, diet and AREDS2 remain the highest-yield levers - modest but real, and available to everyone.

  • New medicines slow, not restore

    Complement inhibitors reduce the rate of atrophy growth - they are not a cure, and expectations need to be set clearly.

How the diagnosis is made

From first symptoms to a mapped, monitored macula.

The steps an optometrist and medical retina team will usually follow, in order - so you know what to expect and why each test matters.

  1. 01

    Assessing

    Symptom history and vision test

    A careful history of reading difficulty, missing letters, dim central vision and paracentral blur - with distance and near visual acuity.

  2. 02

    Assessing

    Amsler grid and contrast check

    Central and paracentral scotomas often show up on Amsler grid; contrast sensitivity is frequently reduced before acuity drops.

  3. 03

    Assessing

    Slit lamp and dilated fundoscopy

    Visible atrophic patches at the macula with a sharp, geographic edge and increased visibility of underlying choroidal vessels.

  4. 04

    Confirming

    Optical coherence tomography (OCT)

    Hallmark features - loss of retinal pigment epithelium and outer retinal layers, with signal enhancement through into the choroid.

  5. 05

    Confirming

    Fundus autofluorescence (FAF)

    The gold standard for GA - hypoautofluorescent atrophy with a hyperautofluorescent junctional zone that predicts growth.

  6. 06

    Planning

    Near-infrared and colour fundus

    Additional imaging to map lesion size and rule out mimics, plus a baseline for measuring progression over time.

  7. 07

    Planning

    Medical retina review

    A specialist opinion to stage disease, plan monitoring, discuss complement inhibitor eligibility and refer for low vision support.

Typical timeline: from optometrist referral to a settled monitoring plan in a few weeks.

Symptoms

What geographic atrophy actually feels like.

A gradual central blur, missing letters and reduced contrast - and the changes that mean it is time to be seen sooner rather than later.

  • Gradual central blur

    A slow smudge in the middle of vision - reading, faces and screens become harder over months and years.

  • Paracentral scotomas

    Small blind spots just off the fixation point that make words or parts of faces vanish as you look at them.

  • Missing letters when reading

    Specific letters or short words disappear from a line of text - a classic clue to macular atrophy.

  • Reduced contrast and dim vision

    The world looks washed out and dim, particularly in poor light - contrast sensitivity often drops before acuity.

  • Slow, steady progression

    Unlike wet AMD, geographic atrophy progresses over years, not weeks - but relentlessly enlarges over time.

  • Bilateral but asymmetric

    Both eyes are usually involved, though one eye is often further ahead than the other at any given point.

  • Difficulty with faces and driving

    Recognising faces at a distance, reading road signs and reacting to central visual cues all become harder.

  • Red flag - sudden distortion or blur

    A sudden change, straight lines looking wavy or a rapid drop in vision suggests conversion to wet AMD and needs urgent review.

Treatment

How geographic atrophy is managed today.

Lifestyle and AREDS2 first, low vision rehabilitation for everyone with functional impact, and complement inhibitors for selected patients. See our page on the geographic atrophy complement inhibitor clinic.

  • Smoking cessation

    The single most important modifiable risk factor for AMD progression - stopping smoking meaningfully slows the disease.

  • Mediterranean-style diet

    Oily fish, leafy greens, nuts, olive oil and coloured vegetables - the diet with the best AMD evidence.

  • AREDS2 supplements

    Vitamins C and E, zinc, copper, lutein and zeaxanthin - proven for intermediate AMD, with some benefit signals in GA.

  • Low vision rehabilitation

    Specialist optometry, magnification aids, eccentric viewing training, lighting advice and assistive technology.

  • Pegcetacoplan (Syfovre)

    An intravitreal anti-C3 complement inhibitor, FDA-approved 2023 for GA, with MHRA approval pending in the UK.

  • Avacincaptad pegol (Izervay)

    An intravitreal anti-C5 complement inhibitor, FDA-approved 2023 - slows atrophy growth but does not restore vision.

  • Ophthalmology monitoring

    Regular medical retina review with imaging to track atrophy growth and detect conversion to wet AMD early.

  • Emerging trials

    Gene therapy, neuroprotection and retinal cell replacement - all in trials, all specialist commissioned, all worth asking about.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, specialist society standards and landmark trials, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your ophthalmologist or optometrist knows your eyes and history, and can tell you which parts apply to you. If in doubt, get seen.

  • Royal College of Ophthalmologists. Age-related macular degeneration - guidelines.

  • NICE. Age-related macular degeneration (NG82).

  • Age-Related Eye Disease Study 2 (AREDS2) research group publications.

  • FDA prescribing information for pegcetacoplan and avacincaptad pegol.

  • Macular Society and RNIB - patient information on geographic atrophy.

Red flags

When to seek urgent review.

Most of geographic atrophy is a slow-motion condition monitored in clinic. These are the exceptions - and the changes that warrant a same-week, or same-day, review.

  • Sudden central blur

    A rapid change in central vision over days rather than months suggests conversion to wet AMD - refer urgently to a hospital eye service.

  • New distortion or wavy lines

    Straight lines looking bent on the Amsler grid is a classic warning sign for choroidal neovascular membrane - urgent same-week ophthalmology review.

  • New floaters or flashes

    These are not typical of geographic atrophy - they need same-day assessment to exclude retinal tear or detachment.

  • Painful red eye

    GA is painless - a painful red eye is a separate emergency and needs urgent ophthalmology assessment.

  • Rapid loss of vision in the second eye

    A sudden second-eye event in someone with known GA warrants urgent medical retina review to look for wet AMD conversion.

  • Post-injection warning symptoms

    After a complement inhibitor injection, worsening pain, redness or vision loss must be reviewed the same day to exclude endophthalmitis.

  • Falls, low mood or isolation

    GA carries a real psychosocial toll - falls, depression and loneliness deserve active support, not just an eye clinic follow-up.

  • Difficulty driving safely

    If central vision no longer meets DVLA standards, driving must stop - the eye clinic can advise on the legal position.

  • A relative with rapid onset AMD

    Very early or fast-progressing macular disease in a family member may hint at an inherited macular dystrophy that mimics AMD.

Living with it

A slow disease, with more levers than most people realise.

Four practical shifts that make the biggest day-to-day difference - lifestyle, low vision help, home monitoring and community support.

A quiet reminder

Independence is engineered, not lucky.

Good lighting, magnification and technology - set up early - keep people reading, cooking and living independently long after acuity has dropped.

  1. 01 Lifestyle

    Stop smoking, eat the diet

    Smoking cessation and a Mediterranean-style diet remain the two lifestyle levers with the strongest evidence for slowing AMD.

  2. 02 Support

    Get low vision help early

    Specialist low vision optometry, magnifiers, lighting and eccentric viewing training add years of independent reading and living.

  3. 03 Monitoring

    Keep an Amsler grid at home

    A short weekly check catches conversion to wet AMD - the one form of macular disease where fast action really changes outcomes.

  4. 04 Community

    Lean on the Macular Society and RNIB

    Peer support, benefits advice and practical technology guidance from national charities help far more than most people expect.

Frequently asked

Everything we get asked about geographic atrophy.

Quick answers on how it differs from wet AMD, whether it can be cured, and where the new complement inhibitors fit.

  • What is geographic atrophy?

    Geographic atrophy is the advanced form of dry age-related macular degeneration. Well-defined patches of retinal pigment epithelium, photoreceptors and underlying choriocapillaris progressively die, producing the characteristic geographic appearance on retinal imaging and causing gradual central vision loss.

  • How is geographic atrophy different from wet AMD?

    Both are advanced AMD. Wet (neovascular) AMD is driven by leaky abnormal blood vessels and typically causes sudden distortion or vision loss over days to weeks. Geographic atrophy progresses slowly over years without leakage, but it is relentless and is the leading cause of severe vision loss from AMD in the UK.

  • Can geographic atrophy be cured?

    Not currently. The goal today is to slow progression, protect the vision that remains and support day-to-day function. Complement inhibitors reduce the rate at which atrophy grows, and lifestyle, AREDS2 supplementation and low vision rehabilitation all add real benefit.

  • Do AREDS2 supplements help?

    AREDS2 supplements - vitamins C and E, zinc, copper, lutein and zeaxanthin - are proven to reduce progression from intermediate AMD to advanced disease and are widely used in geographic atrophy as well. They are not a substitute for stopping smoking or eating well, but they are a sensible addition for most patients.

  • Are the new complement inhibitors available on the NHS?

    Pegcetacoplan and avacincaptad pegol are FDA-approved in the US. MHRA approval and NHS commissioning in the UK are evolving, and access is currently limited and often private. Suitability depends on lesion location, size and how quickly your GA is progressing - a medical retina specialist can advise.

  • Will I go completely blind?

    People with geographic atrophy usually keep their peripheral vision and rarely go completely blind. Central vision - reading, driving and recognising faces - is what suffers most. With low vision support, most people continue to live independently for many years.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.